{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:58:30Z","timestamp":1785355110576,"version":"3.55.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:p>\n                    This study retrospectively analyzes the clinical effect of Xuezhikang capsule combined with epalrestat on type 2 diabetic peripheral neuropathy. A total of 140 patients with type 2 diabetes combined with DPN were selected as the participants, which were divided into treatment group and control group, 70 cases respectively, according to different treatment schemes. The control group of patients received treatment with iprastam (50-mg\/dose, 3 times\/day) on the basis of controlling blood sugar, while the treatment group of patients received oral administration of Xuezhikang capsules (0.6-g\/dose, 2 times\/day) to regulate blood lipids on the basis of the control group\u2019s treatment plan, all treated for 12 weeks. Observe and compare the levels of laboratory indicators, Toronto Clinical Scoring System scores, and nerve conduction velocity before and after treatment between 2 groups of patients. After treatment, the levels of triglycerides, low-density lipoprotein, C-reactive protein, and tumor necrosis factor in the treatment group were measured. The level was lower than before treatment and the control group, while the level of high-density lipoprotein was higher than before treatment and the control group, with a statistically significant difference (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05); after treatment, the Toronto Clinical Scoring System scores of both groups were lower than before treatment, and the treatment group was lower than the control group, with a statistically significant difference; after treatment, the motor conduction velocity of the median nerve and common peroneal nerve, as well as the sensory conduction velocity of the sural nerve, median nerve, and common peroneal nerve in both groups were higher than before treatment, and the treatment group was higher than the control group, with statistical significance (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05); logistic regression analysis showed that high HbA1c, high triglycerides, high C-reactive protein, low high-density lipoprotein, and course of disease were risk factors for diabetes peripheral neuropathy (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). Xuezhikang capsule can improve the blood lipid level and inflammatory factors in patients with type 2 diabetes, and the effect of Xuezhikang capsules combined with Epastatin on improving the conduction velocity, clinical score, and clinical symptoms of peripheral neuropathy\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045549","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:02:16Z","timestamp":1762538536000},"page":"e45549","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Study on the efficacy and safety of Xuezhikang capsule combination with epalrestaton in treating diabetic peripheral neuropathy patients"],"prefix":"10.1097","volume":"104","author":[{"given":"Yuping","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Outpatient, People\u2019s Hospital of Chengyang District, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, People\u2019s Hospital of Chengyang District, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoou","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, People\u2019s Hospital of Chengyang District, Qingdao, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-3286","authenticated-orcid":false,"given":"Xiaopang","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, People\u2019s Hospital of Chengyang District, Qingdao, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260729","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study.","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03007995.2018.1497958","article-title":"Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review.","volume":"35","author":"Amato Nesbit","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41574-021-00496-z","article-title":"Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.","volume":"17","author":"Sloan","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/dc11-0903","article-title":"Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study.","volume":"34","author":"Charles","year":"2011","journal-title":"Diabetes Care"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","article-title":"A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients.","volume":"43","author":"Dhawan","year":"2020","journal-title":"Cancer Nurs"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/jdi.14066","article-title":"Association between hemoglobin glycation index and non-alcoholic fatty liver disease in the patients with type 2 diabetes mellitus.","volume":"14","author":"Wang","year":"2023","journal-title":"J Diabetes Investig"},{"key":"R7-20260729","first-page":"97","article-title":"Chinese expert consensus on the use of Xuezhikang (2017 revised edition).","volume":"57","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"e0153389","DOI":"10.1371\/journal.pone.0153389","article-title":"The relationship between dyslipidemia and acute axonal function in type 2 diabetes mellitus in vivo.","volume":"11","author":"Kwai","year":"2016","journal-title":"PLoS One"},{"key":"R9-20260729","first-page":"12","article-title":"Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition).","volume":"61","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R10-20260729","first-page":"405","article-title":"[Chinese expert consensus on diagnosis and treatment of diabetic optic neuropathy (2022)].","volume":"58","year":"2022","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/IJGM.S160555","article-title":"Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East.","volume":"11","author":"Alshamiri","year":"2018","journal-title":"Int J Gen Med"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.2337\/diacare.25.11.2048","article-title":"Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy.","volume":"25","author":"Bril","year":"2002","journal-title":"Diabetes Care"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/eci.12588","article-title":"Intact FGF23 and \u03b1-Klotho during acute inflammation\/sepsis in CKD patients.","volume":"46","author":"Dounousi","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"R14-20260729","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcjd.2015.08.005","article-title":"Falls and balance impairments in older adults with type 2 diabetes: thinking beyond diabetic peripheral neuropathy.","volume":"40","author":"Hewston","year":"2016","journal-title":"Can J Diabetes"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5348\/D05-2016-7-OA-3","article-title":"Impact of foot progression angle modification on plantar loading in individuals with diabetes mellitus and peripheral neuropathy.","volume":"2","author":"Merriwether","year":"2016","journal-title":"Edorium J Disabil Rehabil"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11011-017-0021-5","article-title":"The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.","volume":"32","author":"Saeedi Saravi","year":"2017","journal-title":"Metab Brain Dis"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"108172","DOI":"10.1016\/j.pharmthera.2022.108172","article-title":"Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl\/eicosapentaenoic acid.","volume":"237","author":"Chapman","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"115700","DOI":"10.1016\/j.jep.2022.115700","article-title":"The effect of Xuezhikang capsule on gene expression profile in brown adipose tissue of obese spontaneously hypertensive rats.","volume":"302","author":"Zhang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/aps.2015.98","article-title":"Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice.","volume":"36","author":"Feng","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"R20-20260729","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.yrtph.2020.104781","article-title":"A 26-week toxicological study of Xuezhikang (XZK), red yeast rice extract, in Beagle dogs with a 4-week recovery period.","volume":"117","author":"Li","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"key":"R21-20260729","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R22-20260729","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1476-5381.2010.01196.x","article-title":"Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.","volume":"164","author":"F\u00f6rstermann","year":"2011","journal-title":"Br J Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:02:06Z","timestamp":1785351726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":22,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045549","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2024-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}